Table 1.
Category of agent | Agent | Mechanism of action | Species | Route of administration | Timing of administration relative to extinction | Reference |
---|---|---|---|---|---|---|
Amino Acid Receptor Modulators | ||||||
D-cycloserine | NMDA receptor partial agonist | human | acute capsule | before | Ressler et al., 2004 | |
D-cycloserine | human | acute oral powder | before | Kuriyama et al., 2011 | ||
D-cycloserine | human | acute capsule | after | Smits et al., 2013 | ||
D-cycloserine | rat | acute s.c. | after | Ledgerwood et al., 2005 | ||
D-cycloserine | rat | acute s.c. | after | Weber et al., 2007 | ||
D-cycloserine | rat | acute s.c. | after | Parnas et al., 2005 | ||
D-cycloserine | rat | acute i.p. | after | Toth et al., 2012 | ||
D-cycloserine | rat | acute s.c. | before | Bouton et al., 2008 | ||
D-cycloserine | rat | acute s.c. | before | Woods and Bouton, 2006 | ||
D-cycloserine | rat | acute: i.p., bilateral basolateral amygdala (BLA) | before | Walker et al., 2002 | ||
D-cycloserine | rat | acute bilateral BLA or LA | before | Mao, 2006 | ||
D-cycloserine | rat | acute i.p. | before | Yang and Lu, 2005 | ||
D-cycloserine | rat | subchronic bilateral dorsal hippocampus | before | Ren et al., 2013 | ||
D-cycloserine, picrotoxin | picrotoxin: GABAA receptor antagonist | rat | acute bilateral infralimbic cortex | before | Chang and Maren, 2011 | |
D-serine | NMDA receptor agonist | mouse | acute i.p. | before | Matsuda et al., 2010 | |
PEPA | AMPA receptor potentiator | mouse | acute: i.p., bilateral mpfc, bilateral amygdala (subregion unspecified) | before | Zushida et al., 2007 | |
bicuculline | GABAA receptor antagonist | rat | acute bilateral or right BLA | after | Berlau and McGaugh, 2006 | |
muscimol | GABAA receptor agonist | rat | acute: bilateral infralimbic, bilateral BLA | before for infralimbic, after for BLA | Akirav et al., 2006 | |
Monoamine Modulators | ||||||
fluoxetine | serotonin reuptake inhibitor | rat | chronic i.p. | before | Deschaux et al., 2011 | |
fluoxetine | rat | chronic i.p. | after | Deschaux et al., 2012 | ||
fluoxetine | rat | chronic i.p. | before | Spennato et al., 2008 | ||
fluoxetine | mouse | chronic (in drinking water) | before | Karpova et al., 2011 | ||
yohimbine | α2 adrenergic antagonist | human | acute capsule | before | Powers et al., 2009 | |
yohimbine | mouse | acute s.c. | before | Cain, 2004 | ||
yohimbine | rat | acute i.p. | before | Janak and Corbit, 2010 | ||
yohimbine | rat | acute i.p. | before | Mueller et al., 2009 | ||
yohimbine | rat | acute i.p. | before | Morris and Bouton, 2007 | ||
norepinephrine | adrenergic agonist | rat | acute bilateral or right BLA | after | Berlau and McGaugh, 2006b | |
isoproterenol | nonselective β adrenergic agonist | rat | subchronic i.p. | after | Do-Monte et al., 2010 | |
propranolol | nonselective β adrenergic antagonist | rat | acute i.p. | before | Rodriguez-Romaguera et al., 2009 | |
methylphenidate | dopamine/norepinephrine reuptake inhibitor | mouse | acute i.p. | before or after | Abraham et al., 2012 | |
L-dopa | dopamine precursor | mouse | acute i.p. | after | Haaker et al., 2013 | |
tandospirone | Serotonin (5HT1A) receptor agonist | rat | acute i.p. | before and after | Saito et al., 2012 | |
Cholinergic, Cannabinoid, and Peptide Modulators | ||||||
sulpiride | dopamine (D2) receptor antagonist | mouse | acute i.p. | before | Ponnusamy et al., 2005 | |
scopolamine | cholinergic muscarinic antagonist | rat | acute i.p. | before | Zelikowsky et al., 2013 | |
cannabidiol | non-psychotomimetic cannabinoid | human | acute, inhaled | after | Das et al., 2013 | |
synthetic THC | cannabinoid (CB1) receptor agonist | human | acute, capsule | before | Rabinak et al., 2013 | |
AM404 | endocannabinoid breakdown (via enzyme fatty acid amide hydrolase (FAAH)) and reuptake inhibitor | rat | acute i.p. | before | Chhatwal et al., 2005 | |
AM404 or cannabidiol | rat | acute i.c.v. | before | Bitencourt et al., 2008 | ||
AM404 or WIN55212-2 | WIN55212-2: CB1 agonist | rat | acute i.p. | before | Pamplona et al., 2008 | |
WIN55212-2 | rat | acute i.p. | before | Pamplona et al., 2006 | ||
WIN55212-2 | rat | acute unilateral (left or right) infralimbic | before | Lin et al., 2009 | ||
AM3506 | FAAH inhibitor | mouse | acute bilateral BLA or acute i.p. | before | Gunduz-Cinar et al., 2012 | |
neuropeptide Y | agonist at its own receptors (Y1 – Y5) | rat | acute unilateral (left or right) lateral ventricle | before | Lach and de Lima, 2013 | |
neuropeptide Y | rat | acute left lateral ventricle | before | Gutman et al., 2008 | ||
neuropeptide S | agonist at its own receptor (NPSR) | mouse | acute bilateral LA/BLA | before | Jungling et al., 2008 | |
Steroid Hormone Modulators | ||||||
cortisol | agonist of steroid receptors | human | acute tablet | before | de Quervain et al., 2011 | |
corticosterone | agonist of steroid receptors | mouse | acute i.p. | before | Brinks et al., 2009 | |
dexamethasone (by itself or with D-cycloserine) | agonist of steroid receptors | rat | acute i.p. | before | Yang et al., 2007 | |
dexamethasone | rat | acute i.p. | before | Yang et al., 2006 | ||
RU28362 | glucocorticoid receptor agonist | rat | acute bilateral BLA | before | Yang et al., 2006 | |
estrogen and/or progesterone | agonists of their endogenous receptors | rat (females in metestrus) | acute s.c. | before | Milad et al., 2009 | |
diarylpropionitrile | estrogen receptor B (ERB) agonist | rat (ovariectomized) | two i.p. injections | before | Chang et al., 2009 | |
diarylpropionitrile or estradiol | rat (ovariectomized) | acute bilateral dorsal hippocampus | before | Chang et al., 2009 | ||
Other Modulators | ||||||
valproic acid or sodium butyrate | histone deacetylase (HDAC) inhibitors | mouse | acute i.p. | before | Bredy et al., 2007 | |
sodium butyrate | mouse | acute s.c. | before | Lattal et al., 2007 | ||
trichostatin A | HDAC inhibitor | mouse | acute bilateral dorsal hippocampus | before | Lattal et al., 2007 | |
valproic acid | mouse | acute i.p. | before | Bredy and Barad, 2008 | ||
valproic acid | mouse | repeated i.p. injections | after | Heinrichs et al., 2013 | ||
vorinostat | HDAC inhibitor | rat | acute i.p. | after | Matsumoto et al., 2013 | |
RGFP966 | HDAC3 inhibitor | mouse | acute s.c. | after | Malvaez et al., 2013 | |
SPV106 | activator of p300/CBP-associated factor (PCAF) | mouse | acute i.p. | before or after | Wei et al., 2012 | |
fibroblast growth factor-2 | agonist of fibroblast growth factor receptor 1 | rat | acute s.c. | before or after | Graham and Richardson, 2009 | |
fibroblast growth factor-2 | rat | acute s.c. | after | Graham and Richardson, 2010 | ||
fibroblast growth factor-2 | rat | acute bilateral BLA | after | Graham and Richardson, 2011 | ||
magnesium-L-threonate | multifunctional biological activity | rat | chronic, drinking water | before | Abumaria et al., 2011 | |
XE-991 | M-type K+ channel blocker | rat | acute, principally unilateral infralimbic cortex | before | Santini and Porter, 2010 | |
7,8 dihydroxyflavone | TrkB agonist | mouse | acute i.p. | before | Andero et al., 2011 |
Only agents that enhanced extinction, either within session or during subsequent retrieval or renewal tests, are included. If route of administration indicates a brain structure, this means the drug was infused into that structure. Abbreviations: intraperitoneal (i.p.), subcutaneous (s.c.), basolateral amygdala (BLA), lateral amygdala (LA).